IBO director sells 50,000 Impact Biomedical shares

IMPACT BIOMEDICAL INC. director Jason Grady reported an open-market sale of 50,000 shares of common stock at an average price of $0.6501 per share.

Rhea-AI Filing Summary

IMPACT BIOMEDICAL INC. director Jason Grady reported an open-market sale of 50,000 shares of common stock at an average price of $0.6501 per share. After the transaction, he directly holds 250,182 common shares, indicating he retains a substantial ongoing equity stake in the company.

Insights

Equity analyst

IBO director executes a moderate open-market share sale while keeping a sizeable stake.

Director Jason Grady sold 50,000 shares of IMPACT BIOMEDICAL INC. common stock in an open-market transaction at $0.6501 per share. This is a discretionary sale, not a tax withholding, grant, or option exercise.

Following the sale, he holds 250,182 common shares directly, so the filing shows a reduction but not an exit of his position. There are no derivative holdings reported, suggesting his equity exposure now comes entirely from common shares disclosed here.

Insider Trade Summary

Net Seller: 50,000 shares

Net Sell 1 txn

Insider Grady Jason

Role Director

Sold 50,000 shs ($33K)

Type	Security	Shares	Price	Value
Sale	Common Stock	50,000	$0.6501	$33K

Holdings After Transaction: Common Stock — 250,182 shares (Direct)

FAQ

What insider transaction did IMPACT BIOMEDICAL (IBO) director Jason Grady report?

Director Jason Grady reported selling 50,000 shares of IMPACT BIOMEDICAL common stock. The shares were sold in an open-market transaction at an average price of $0.6501 per share, according to the Form 4 insider trading disclosure.

At what price did Jason Grady sell IBO stock in this Form 4 filing?

Jason Grady sold his IMPACT BIOMEDICAL common shares at an average price of $0.6501 per share. This reflects the per-share consideration received in the reported open-market transaction on the filing date.

How many IMPACT BIOMEDICAL (IBO) shares did Jason Grady sell and how many does he now hold?

Jason Grady sold 50,000 shares of IMPACT BIOMEDICAL common stock. After this transaction, he directly holds 250,182 common shares, showing he reduced but did not eliminate his ownership position in the company.

Is the Jason Grady IBO insider transaction an open-market sale or another type of trade?

The transaction is an open-market sale of common stock by director Jason Grady. It is coded as an “S” transaction, meaning a sale in the open market or a private transaction, not a grant, option exercise, gift, or tax withholding event.

Does Jason Grady have any derivative securities reported in this IBO Form 4?

No derivative securities are reported for Jason Grady in this filing. The disclosure only lists a non-derivative transaction in common stock, indicating his current reported exposure is through directly held common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 07:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grady Jason

(Last) (First) (Middle)

1093 CARRINGTON WAY

(Street)

VICTOR NEW YORK 14564

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMPACT BIOMEDICAL INC. [ IBO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		S		50,000	D	$0.6501	250,182	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This entity is a wholly-owned subsidiary of DSS, Inc.

	/s/ Jason Grady	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)